Repatha Reduces First Cardiovascular Events by 31%
Amgen announced on March 28, 2026, that its cholesterol-lowering drug Repatha (evolocumab) cut the risk of a first major adverse cardiovascular event by 31% in high-risk patients. The results stem from a subgroup analysis of the Phase 3 VESALIUS-CV trial, which focused on 3,655 diabetic patients without known significant atherosclerosis. The findings, presented at the American College of Cardiology's 75th Annual Scientific Session, showed Repatha decisively reduced the composite endpoint of coronary heart disease death, myocardial infarction, or ischemic stroke when added to standard statin therapy.
Beyond the primary endpoint, the data revealed consistent benefits across secondary measures. Repatha demonstrated numerical risk reductions for heart attacks by 31%, ischemia-driven revascularization by 34%, and ischemic stroke by 33%. These strong results in a primary prevention setting—treating patients before they have a major cardiac event—underscore the drug's potential to shift treatment paradigms.
Data Paves Way for Expanded Primary Prevention Market
The trial's success in lowering low-density lipoprotein cholesterol (LDL-C) to a median of 44 mg/dL, compared to 105 mg/dL in the placebo group, provides a strong rationale for earlier and more intensive intervention. This level of reduction is often difficult to achieve with statins or ezetimibe alone, positioning Repatha as a powerful tool for a broader patient population. The results could support an expanded FDA label for Repatha, unlocking a significant new market focused on preventing first-time cardiovascular events in high-risk individuals.
The evidence is unequivocal: Intensive LDL-C lowering with Repatha significantly reduces the risk of major CV events for high-risk patients.
— Jay Bradner, M.D., Executive Vice President of Research and Development at Amgen.
This strategy aligns with updated cardiology guidelines that advocate for more aggressive cholesterol management. By proving its efficacy before significant arterial plaque develops, Amgen makes a compelling case for using Repatha not just as a treatment after a heart attack, but as a crucial preventative measure, which could significantly boost future revenue streams for the blockbuster drug.
